ABSORPTION OF ORALLY SUPPLIED NATURAL ESTROGENS CORRELATED WITH AGE AND SOMATOMETRIC PARAMETERS

被引：1

作者：

HARTMANN, BW

KIRCHENGAST, S

ALBRECHT, A

SOREGY, G

KNOGLER, W

HUBER, JC

机构：

[1] First Department of Gynecology and Obstetrics, University of Vienna Medical School, Allgemeines Krankenhaus, Vienna

[2] Institute of Medical and Chemical Laboratories, University of Vienna Medical School, Allgemeines Krankenhaus, Vienna

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1994年 / 8卷 / 02期

关键词：

POSTMENOPAUSAL; ESTRADIOL VALERATE; MICRONIZED ESTRADIOL; SOMATOMETRIC CHARACTERISTICS; REPLACEMENT THERAPY;

D O I：

10.3109/09513599409058030

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The plasma levels of estradiol were studied in 20 post-menopausal women over a period of 8 h following the ingestion of a single dose of 2 mg estradiol valerate and 2 mg micronized estradiol. The determined plasma estradiol concentrations were correlated with somatometric characteristics and age. Twenty-six postcephalic body measurements, the body weight and six skin-fold thickness measurements were taken and the body mass index computed; estradiol serum concentration was measured before and after administration of micronized estradiol and estradiol valerate, respectively. It was shown that estradiol concentrations obtained after estradiol valerate and micronized estradiol ingestion were dependent on the patient's age as well as on the constitutional type. Additionally, we found that there were differences in the reachable estradiol plasma concentrations following the application of the two preparations. Our results justify the individual and differentiated estrogen replacement therapy of the postmenopausal woman.

引用

页码：101 / 107

页数：7

共 18 条

[11]

Fink B.J., Strid Christensen M., Bioavailability of oestradiol and oestriol administered orally to oophorectomized women, Maturitas, 3, pp. 289-294, (1981)

[12]

Yen S.S.C., Martin P.L., Burnier A.M., Czekala N.M., Greany M.O., Callantine M.R., Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17β-estradiol in postmenopausal women, J. Clin. Endocrinol. Metab., 40, pp. 518-521, (1975)

[13]

Leyendecker G., Geppert G., Nocke W., Ufer J., Untersuchungen zur Pharmakokinetik von Östradiol-17β, Ostradiol-Benzoat, Ostradiol-Valerianat und Östradiol-Undezylat bei der Frau: Der Verlauf der Konzentrationen von Östradiol-17β, Östeon, LH and FSH im Serum, Geburtsh. Frauenheilk., 35, pp. 370-374, (1975)

[14]

Dusterberg B., Schmidt-Gollwitzer M., Huimpel M., Pharmacokinetics of estradiol valerate in ovariectomized women, Horm. Res., 21, pp. 145-154, (1985)

[15]

Sherwin B.B., The impact of different doses of estrogen and progestin on mood and sexual behaviour in postmenopausal women, J. Clin. Endocrinol. Metab., 72, pp. 336-343, (1991)

[16]

Bewley S., Bewley T.H., Drug dependence with oestrogen replacement therapy, Lancet, 339, pp. 290-291, (1992)

[17]

Lindsay R., Hart D.M., Clare D.M., The minimum effective dose of estrogen for prevention of postmenopausal bone loss, Obstet. Gynecol., 63, pp. 759-763, (1984)

[18]

Horsman A., Johnes M., Francis R., Nordin C., The effect of estrogen dose on postmenopausal bone loss, N. Engl. J. Med., 309, pp. 1405-1410, (1983)

← 1 2 →